These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14974876)

  • 1. The NICE reference case requirement: implications for drug manufacturers and health systems.
    Langley PC
    Pharmacoeconomics; 2004; 22(4):267-71. PubMed ID: 14974876
    [No Abstract]   [Full Text] [Related]  

  • 2. The NICE reference case requirement: more pain for what, if any, gain?
    Gafni A; Birch S
    Pharmacoeconomics; 2004; 22(4):271-3. PubMed ID: 14974877
    [No Abstract]   [Full Text] [Related]  

  • 3. Could or Should We Use MCDA in the French HTA Process?
    Ghabri S; Josselin JM; Le Maux B
    Pharmacoeconomics; 2019 Dec; 37(12):1417-1419. PubMed ID: 31565761
    [No Abstract]   [Full Text] [Related]  

  • 4. Crossing the fourth hurdle.
    Rawlins MD
    Br J Clin Pharmacol; 2012 Jun; 73(6):855-60. PubMed ID: 22404227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective.
    Earnshaw J; Lewis G
    Pharmacoeconomics; 2008; 26(9):725-7. PubMed ID: 18767892
    [No Abstract]   [Full Text] [Related]  

  • 6. DEFINING INNOVATION WITH RESPECT TO NEW MEDICINES: A SYSTEMATIC REVIEW FROM A PAYER PERSPECTIVE.
    de Solà-Morales O; Cunningham D; Flume M; Overton PM; Shalet N; Capri S
    Int J Technol Assess Health Care; 2018 Jan; 34(3):224-240. PubMed ID: 29987996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The French Sunshine Act: false transparency.
    Prescrire Int; 2013 Sep; 22(141):223. PubMed ID: 24171223
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
    Hamers FF; Ghabri S; Le Gales C
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NICE: faster access to modern treatments? Analysis of guidance on health technologies.
    Raftery J
    BMJ; 2001 Dec; 323(7324):1300-3. PubMed ID: 11731399
    [No Abstract]   [Full Text] [Related]  

  • 12. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput magnetic resonance imaging.
    Golding SJ
    Acad Radiol; 1996 Apr; 3 Suppl 1():S53. PubMed ID: 8796513
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
    Chauhan D; Miners AH; Fischer AJ
    Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Values and evidence colliding: health technology assessment in child health.
    Ungar WJ; Prosser LA; Burnett HF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
    [No Abstract]   [Full Text] [Related]  

  • 17. [Excellence, the great conformism].
    Kiefer B
    Rev Med Suisse; 2015 Apr; 11(472):1000. PubMed ID: 26062234
    [No Abstract]   [Full Text] [Related]  

  • 18. Market opportunities and technology trends in point of care diagnostics - SMi conference.
    Shirvill J
    IDrugs; 2006 Apr; 9(4):263-5. PubMed ID: 16596479
    [No Abstract]   [Full Text] [Related]  

  • 19. [Health technology assessment: a multidisciplinary approach for selecting innovations in the health service].
    Cavallo MC
    G Ital Nefrol; 2013; 30(3):. PubMed ID: 23832477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.